Phapros Records Net Profit Growth of Up to 109% in 2025, Driven by Significant Sales Increase & Production Cost Efficiency

JAKARTA, April 1, 2026 – PT Phapros Tbk, a leading national pharmaceutical company, successfully bounced back amidst various domestic and global challenges throughout 2025. The issuer with the stock code PEHA successfully recorded a net profit of Rp27.44 billion from January to December 2025, an increase of 109% compared to the same period the previous year, which still recorded a loss of Rp290.63 billion. Not only that, this brilliant performance in 2025 also far exceeded the 2023 achievement, which only recorded a profit of Rp6.01 billion.

PEHA's glowing performance in 2025 was driven by double-digit sales growth and the success of its operational efficiency strategy. Phapros successfully recorded sales in 2025 amounting to Rp940.88 billion, a significant increase of 26.34% year-on-year (y-o-y).

The increase in sales occurred across all product segments. The over-the-counter (OTC) segment rose 43.20% y-o-y, the branded generic (OGB) segment grew 13.95% y-o-y, and the ethical segment surged by 54.94% y-o-y.

Additionally, throughout 2025, the company was also able to reduce production costs or cost of goods sold (COGS) by 5.41% to Rp448.37 billion compared to the previous year's Rp474.03 billion. This excellent performance was further strengthened by the company's ability to reduce operating expenses, which were successfully lowered by 14.64% to Rp406.43 billion in 2025 compared to Rp476.12 billion in 2024. As a result, PEHA successfully recorded very significant net profit growth in 2025 of 109% (y-o-y).

Spirit of Rising Up to Unify Goals

Ida Rahmi Kurniasih, Acting President Director of PT Phapros Tbk., stated that the positive achievement of Phapros' financial performance was the result of the company's determination at the beginning of 2025 to rise up and unify goals. Phapros took strategic steps by conducting business and marketing transformations and optimizing the product portfolio, which also became an important factor in driving sales growth.

The company also continues to carry out production cost efficiencies through a number of innovations across various lines and improving distribution effectiveness, thus successfully cutting operating expenses significantly.

"The spirit of rising up to unify goals has yielded positive results. This achievement is the result of five performance improvement strategies consistently implemented by the company. Improvements in business fundamentals have driven sales growth in all segments, thereby successfully returning the company to sustainable profitability. We are optimistic that the 2025 financial performance will be a good stepping stone to strengthen financial performance and sustainable profitability in the future. Phapros is committed to continuing to develop the business and product portfolio as well as implementing transformation strategies in both core business and supporting aspects," said Ida on Wednesday (1/4/2026).

According to her, this is the fruit of strengthening Sales and Operation Planning discipline, increasing the competence of the marketing team, organizing cooperation with distributors, product portfolio strategies, and strict cost efficiency. This strategy has proven capable of reversing the company's fundamental performance from a loss to a profit. Product portfolio management successfully increased sales in all product segments, including OTC, OGB, and ethical.

More Efficient Production Process

The cost restructuring strategy also proved successful in achieving production efficiency. This can be seen from the 5.41% decrease in COGS. The ratio of COGS to sales in 2025 also dropped significantly to 47.65% compared to 63.65% in 2024. The low ratio of COGS to sales indicates that the production process is running very efficiently with a larger gross profit margin. PEHA also successfully cut marketing and distribution costs by 27.8% y-o-y.

Another positive achievement is the successful reduction of liabilities in 2025 to Rp959.70 billion, a 7.45% (y-o-y) decrease compared to Rp1,036.92 billion in 2024. The success in cutting liabilities has driven an increase in equity in 2025 to Rp427.47 billion, up 8.74% compared to the previous year's Rp393.12 billion. This equity growth also signifies that the company is becoming more valuable to its owners/shareholders.

In addition to profit, Phapros was also able to maintain cash flow well. Net cash flow from the company's operating activities was positive at Rp123.757 billion, with a cash balance of Rp120.98 billion as of December 31, 2025, up 31.49% compared to the same period the previous year at Rp92 billion.

New Product Innovation

Ida explained that innovation is a key factor in supporting sales growth. The latest research results generated by the Phapros R&D team have significantly increased sales in government program medicine tenders. This was achieved by launching a new OAT (anti-TB drug) Category 1 Daily Dose. This product has opened opportunities to actively participate in the control and treatment of tuberculosis (TBC) in Indonesia.

Furthermore, at the end of 2025, PEHA also launched a new product for the health and stamina of adult men in a modern dosage form, namely Orodispersible Film (ODF), which has many advantages compared to conventional dosages. This further affirms PEHA's commitment to supporting health improvements for the people of Indonesia.

Ida added that amidst increasingly tight competition in the pharmaceutical industry, Phapros continues to take various strategic steps to improve the company's competitiveness, especially with a commitment to fulfilling the latest CPOB (GMP) standards and making consumer satisfaction the main focus of its business.

"We continue to drive innovation, digitalization, and efficiency in various internal aspects so that Phapros can continue to grow healthier and more sustainably, as well as be able to meet the needs of the community that has remained loyal as our customers".

"With increasingly strong business fundamentals and strategies, we are optimistic that the company's performance will continue to improve and be able to provide added value to all stakeholders," Ida concluded.